** Brokerage Scotiabank upgrades life sciences tool maker Waters Corp WAT.N rating to "sector outperform" from "sector perform", raises PT to $450 from $430
** Brokerage says the rating is based on WAT's strong Q4 financial performance and 2025 profit forecast
** The price target is justified due to the timing of its clients' instrument replacement cycles, significant revenue from life science applications, and a leading position in emerging markets such as GLP-1 obesity drugs and generic drugs in India - Scotiabank
** "On the bottom line, WAT continues to have significant EPS leverage, driven by its industry leading margins, recently initiated productivity and pricing initiatives and cash deployment capacity" - brokerage
** Stock rose 21.7% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。